Strategic Partners (STRAP) H1 2025 earnings summary

Executive summary

• Reported a net loss of DKK 1.2 million for H1 2025, down from a profit of DKK 1.8 million in H1 2024.

• Sold strategic position in CombiGene AB in January 2025, generating a net profit of DKK 0.4 million until sale.

• In process of liquidating US and Swiss subsidiaries, expecting completion in 2025; will remain as Danish parent company.

Financial highlights

• Operating expenses for H1 2025 were DKK 1.4 million, slightly lower than DKK 1.5 million in H1 2024.

• Operating loss of DKK 1.4 million in H1 2025 versus operating profit of DKK 1.7 million in H1 2024.

• Net cash outflow from operating activities was DKK 4.6 million in H1 2025, compared to DKK 0.3 million in H1 2024.

• Market capitalization at June 30, 2025 was DKK 41.7 million, up from DKK 34.2 million a year earlier.

Outlook and guidance

• Outlook for 2025 revised to an operating loss of DKK -2 to -3 million, improved from previous guidance of DKK -3 to -4 million.

• Forward-looking statements are subject to significant risks and uncertainties, with actual results potentially differing materially.